Characteristics (mean ± SD or n(%)) | Total (n = 410) | Unweighted | Greedy matching | Stabilized IPTW | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Tofacitinib | Adalimumab | SMD | Tofacitinib | Adalimumab | SMD | Tofacitinib | Adalimumab | SMD | ||
(n = 281) | (n = 129) | (n = 139) | (n = 92) | (n = 226) | (n = 99) | |||||
CCI score | ||||||||||
 0 | 339 (82.68) | 229 (81.5) | 110 (85.27) | 0.108 | 119 (85.61) | 79 (85.87) | 0.062 | 187 (82.76) | 80 (83.04) | 0.068 |
 1 | 58 (14.15) | 42 (14.95) | 16 (12.4) | 18 (12.95) | 11 (11.96) | 33 (14.52) | 15 (15.22) | |||
 2 ≤  | 13 (3.17) | 10 (3.56) | 3 (2.33) | 2 (1.44) | 2 (2.17) | 6 (2.72) | 2 (1.74) | |||
Disease duration (months) | 67.38 ± 70.13 | 71.32 ± 70.52 | 58.87 ± 68.79 | 0.179 | 59.15 ± 62.59 | 61.05 ± 71.87 | 0.028 | 70.72 ± 70.00 | 67.92 ± 80.92 | 0.037 |
Duration of current treatment (months) | 11.33 ± 5.11 | 11.23 ± 4.93 | 11.55 ± 5.49 | 0.061 | 11.07 ± 4.97 | 11.25 ± 5.34 | 0.035 | 11.26 ± 4.99 | 11.19 ± 5.25 | 0.014 |
Concomitant use of MTX | ||||||||||
 Yes | 331 (81.73) | 211 (75.63) | 120 (95.24) | 0.579 | 128 (92.09) | 87 (94.57) | 0.099 | 180 (79.94) | 81 (83.27) | 0.086 |
 No | 74 (18.27) | 68 (24.37) | 6 (4.76) | 11 (7.91) | 5 (5.44) | 45 (20.06) | 16 (16.73) | |||
MTX dose (1000 mg) | 2.07 ± 2.81 | 1.96 ± 2.82 | 2.31 ± 2.78 | 0.124 | 2.26 ± 3.09 | 2.35 ± 2.66 | 0.030 | 2.09 ± 2.99 | 2.37 ± 2.97 | 0.095 |
Concomitant use of NSAIDs | ||||||||||
 Yes | 289 (70.49) | 200 (71.17) | 89 (68.99) | 0.048 | 104 (74.82) | 67 (72.83) | 0.045 | 163 (72.17) | 70 (72.05) | 0.003 |
 No | 121 (29.51) | 81 (28.83) | 40 (31.01) | 35 (25.18) | 25 (27.17) | 63 (27.84) | 27 (27.95) | |||
Concomitant use of steroid | ||||||||||
 Yes | 289 (70.49) | 202 (71.89) | 87 (67.44) | 0.097 | 99 (71.22) | 61 (66.3) | 0.106 | 156 (69.34) | 67 (69.12) | 0.005 |
 No | 121 (29.51) | 79 (28.11) | 42 (32.56) | 40 (28.78) | 31 (33.7) | 69 (30.66) | 30 (30.88) | |||
DAS28-CRP | 2.67 ± 1.17 | 2.65 ± 1.16 | 2.71 ± 1.19 | 0.052 | 2.67 ± 1.16 | 2.768 ± 1.212 | 0.082 | 2.705 ± 1.233 | 2.826 ± 1.348 | 0.094 |
DAS28-ESR | 3.33 ± 1.30 | 3.35 ± 1.26 | 3.30 ± 1.39 | 0.032 | 3.31 ± 1.17 | 3.320 ± 1.396 | 0.010 | 3.380 ± 1.297 | 3.434 ± 1.551 | 0.038 |
DAS28 components | ||||||||||
 ESR (mm/h) | 24.63 ± 20.06 | 25.07 ± 18.93 | 23.69 ± 22.37 | 0.066 | 22.66 ± 15.25 | 23.17 ± 20.81 | 0.028 | 25.17 ± 18.36 | 27.48 ± 25.81 | 0.103 |
 CRP | 4.00 ± 9.27 | 3.97 ± 9.77 | 4.07 ± 8.12 | 0.012 | 4.31 ± 12.72 | 4.81 ± 9.20 | 0.045 | 4.76 ± 13.58 | 6.22 ± 10.09 | 0.123 |
 Tender joint count | 2.74 ± 3.95 | 2.58 ± 3.84 | 3.09 ± 4.18 | 0.126 | 2.73 ± 4.00 | 3.11 ± 4.13 | 0.092 | 2.88 ± 4.36 | 3.12 ± 4.72 | 0.051 |
 Swollen joint count | 1.909 ± 3.832 | 1.793 ± 3.721 | 2.164 ± 4.068 | 0.095 | 1.892 ± 3.812 | 2.21 ± 4.02 | 0.080 | 2.13 ± 4.33 | 2.41 ± 4.68 | 0.061 |
 GH VAS | 28.96 ± 20.62 | 29.93 ± 21.15 | 26.89 ± 19.37 | 0.150 | 29.07 ± 20.88 | 27.32 ± 19.53 | 0.086 | 29.00 ± 21.11 | 29.68 ± 20.58 | 0.033 |